With respect to AML this theory was supported by genomic sequencing data showing the presence of Classes I and II mutations such as FLT3 (tyrosine kinase) and NPM1 (nucleophosmin) in CN-AML patients with no other identifiable chromosomal abnormalities [72]. This evidence concerns the gene FLT3 and acute myeloid leukemia.